{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=45", "query": { "intervention": "Placebo (Cohort 3)", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1069, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+3%29&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T12:17:45.909Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01091142", "title": "Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "NP001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neuraltus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 56, "start_date": "2010-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-10-06", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 3, "location_summary": "San Francisco, California • Kansas City, Kansas • Lexington, Kentucky", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01091142" }, { "nct_id": "NCT02698657", "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "ASP5094", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2016-02-23", "completion_date": "2017-09-07", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 7, "location_summary": "Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "DeBary", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02698657" }, { "nct_id": "NCT07158437", "title": "Phase 1 Study of SL-325 in Healthy Volunteers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "SL-325", "type": "BIOLOGICAL" }, { "name": "Placebo (Normal Saline)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Shattuck Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 72, "start_date": "2025-09-18", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07158437" }, { "nct_id": "NCT01755767", "title": "Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tivantinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 383, "start_date": "2012-12-27", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01755767" }, { "nct_id": "NCT04213807", "title": "A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "MAA868 Cohort 1", "type": "BIOLOGICAL" }, { "name": "MAA868 Cohort 2", "type": "BIOLOGICAL" }, { "name": "MAA868 Cohort 3", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Anthos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 28, "start_date": "2019-12-11", "completion_date": "2021-03-08", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 6, "location_summary": "Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Alexandria", "state": "Louisiana" }, { "city": "Lansing", "state": "Michigan" }, { "city": "Wynnewood", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04213807" }, { "nct_id": "NCT03608371", "title": "BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson Disease", "Motor Disorder" ], "interventions": [ { "name": "BTRX-246040", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BlackThorn Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "30 Years to 76 Years" }, "enrollment_count": 24, "start_date": "2018-08-31", "completion_date": "2019-04-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 4, "location_summary": "Hallandale, Florida • Farmington Hills, Michigan • Durham, North Carolina + 1 more", "locations": [ { "city": "Hallandale", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03608371" }, { "nct_id": "NCT07287033", "title": "Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peanut Allergies" ], "interventions": [ { "name": "MY006 Low Dose", "type": "DRUG" }, { "name": "MY006 Mid Dose", "type": "DRUG" }, { "name": "MY006 High Dose", "type": "DRUG" }, { "name": "MY006 Selected Dose", "type": "DRUG" }, { "name": "Placebo (Vehicle)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mabylon AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "12 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2025-12-06", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287033" }, { "nct_id": "NCT03711500", "title": "D-serine Augmentation of Neuroplasticity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Schizophrenia", "Schizo Affective Disorder" ], "interventions": [ { "name": "D-serine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2019-03-13", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 2, "location_summary": "New York, New York • Orangeburg, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Orangeburg", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03711500" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT01193478", "title": "A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2010-08", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2013-01-21", "last_synced_at": "2026-10-18T12:17:45.909Z", "location_count": 13, "location_summary": "Anaheim, California • Cypress, California • National City, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193478" } ] }